ERBB2 and ovarian carcinoma: Furthermore, in vivo studies proved that SYD985 is significantly more active than T-DM1 against HER2 positive epithelial ovarian cancer (EOC) xenografts with moderate to low heterogeneous HER2 expressions [5].